| PubMed |
Abstract |
RScore(About this table) |
| 10937518 |
Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F: Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2000 Aug;23(8):1177-81.
|
2(0,0,0,2) |
Details |
| 11437866 |
Bosi E, Minelli R, Bazzigaluppi E, Salvi M: Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?. Diabet Med. 2001 Apr;18(4):329-32.
|
2(0,0,0,2) |
Details |
| 18282420 |
Xin Y, Zhao YQ, Zhao YX, Zhang LH: [The changes of serum interferon-inducible protein-10 levels in children with type 1 diabetes mellitus]. Zhonghua Er Ke Za Zhi. 2007 Nov;45(11):853-5.
|
2(0,0,0,2) |
Details |
| 11276368 |
Crow M, Taub DD, Cooper S, Broxmeyer HE, Sarris AH: Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes. J Hematother Stem Cell Res. 2001 Feb;10(1):147-56.
Human recombinant interferon-inducible protein-10 (rIP-10), a C-X-C chemokine, inhibits proliferation of human hematopoietic progenitors responsive to co-stimulation by recombinant steel factor (rSLF), is chemotactic for human monocytes and T-lymphocytes, and promotes T-lymphocyte adhesion to endothelial cells. |
1(0,0,0,1) |
Details |